Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks Real-World use of eczema drug abrocitinib

NCT ID NCT06353087

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 19, 2026 · Updated 4 times

Summary

This study follows 200 people aged 12 and older with moderate-to-severe eczema who are starting a new prescription of abrocitinib. Researchers will track how much their skin improves over 12 months using standard eczema severity scores. The goal is to see how well the drug works in real-world settings, outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
abrocitinib
What this could lead to
If successful, this study could confirm that abrocitinib works well in real-world settings for people with moderate-to-severe eczema, helping doctors make better treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only follows people for 12 months, and long-term effects or rare side effects may not be captured.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

41 people

The number who actually took part.

Started

Jun 2024

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult and pediatric AD patients ≥12 years with moderate-to-severe atopic dermatitis receiving abrocitinib.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: 1. Patients aged ≥12 years 2. Patients with confirmed diagnosis of moderate-to-severe AD as assessed by the physician 3. Patients for whom the physician's decision has been made to newly prescribe abrocitinib in usual clinical practice conditions 4. Evidence of a personally signed and dated informed consent/assent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study Exclusion Criteria: Patients meeting any of the following criteria will not be included in the study: 1. Any prior use of abrocitinib 2. Simultaneous participation in a study that includes administration of any investigational drug or procedure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema immune system disorder skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dermatitis Dermatitis, atopic Eczema Immune system diseases Janus kinase inhibitors Skin diseases

Contacts and locations

Locations

  • Chang Gung Hospital Linkou

    Taoyuan, 333, Taiwan

  • Chang Gung Memorial Hospital at Kaohsiung

    Kaohsiung City, 83301, Taiwan

  • Kaohsiung Medical University Hospital

    Kaohsiung City, 807377, Taiwan

  • MacKay Memorial Hospital

    Taipei, 10449, Taiwan

  • NTUH

    Taipei, 100, Taiwan

  • Taipei Medical University - Shuang Ho Hospital

    New Taipei City, 23561, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • Tri-Service General Hospital

    Taipei, 11490, R.O.C., Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.